Check-Cap (NASDAQ:CHEK) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a report published on Tuesday. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Stock Performance

NASDAQ:CHEK opened at $2.29 on Tuesday. Check-Cap has a 52 week low of $1.27 and a 52 week high of $4.63. The firm has a 50-day moving average price of $2.25 and a two-hundred day moving average price of $2.57. The firm has a market cap of $13.40 million, a price-to-earnings ratio of -0.76 and a beta of 0.27.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.